Good afternoon :)
Place Order
Add to Watchlist

Healthcare Global Enterprises Ltd

HCG Share Price

526.204.97% (+24.90)

HCG Share Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹6,988 cr, stock is ranked 609
Moderate RiskStock is 2.22x as volatile as Nifty

HCG Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹6,988 cr, stock is ranked 609
Moderate RiskStock is 2.22x as volatile as Nifty

HCG Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
119.858.08
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.256.290.54%

HCG Analyst Ratings & Forecast

Detailed Forecast 
86%
Analysts have suggested that investors can buy this stock

from 7 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

HCG Company Profile

Healthcare Global Enterprises Limited is a specialty healthcare provider. The Company is focused on cancer and fertility.

Investor Presentation

View older 

Feb 16, 2025

PDF
View Older Presentations

HCG Similar Stocks (Peers)

Compare with peers 
PE Ratio
104.40
1Y Return
49.88%
Buy Reco %
73.68
PE Ratio
103.60
1Y Return
4.86%
Buy Reco %
86.21
PE Ratio
79.08
1Y Return
56.80%
Buy Reco %
100.00
PE Ratio
43.38
1Y Return
40.76%
Buy Reco %
66.67
PE Ratio
92.25
1Y Return
2.56%
Buy Reco %
71.43
Compare with Peers
HCG Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly

HCG Stock Summary · November 2024

The company has achieved remarkable financial performance, reporting a historic quarterly revenue growth of 14% year-over-year, driven by a strong oncology segment and a significant increase in digital channel revenue. However, challenges in international markets, particularly a 17% decline due to geopolitical issues, have prompted a strategic focus on domestic expansion and acquisitions. While emerging centers like Kolkata and Mumbai show promising growth, existing facilities face operational hurdles, impacting overall profitability. The commitment to innovation and patient-centric care, alongside a robust digital transformation strategy, positions the company favorably for future growth, despite the need for improvements in certain centers. Overall, the outlook remains optimistic, with management confident in achieving targeted EBITDA margins and enhancing operational efficiencies.

Key Points on HCG Stock Performance
HCG Stock Growth Drivers
7
  • Strong Financial Performance

    The company reported its best quarterly results in history for Q2 and H1 FY '25,

  • Expansion and Growth Initiatives

    The company is focusing on strategic acquisitions to accelerate growth, having completed two acquisitions in

HCG Stock Challenges
4
  • Declining Financial Performance

    The company is experiencing a decline in EBITDA at existing centers, with ongoing challenges in

  • Impact of One-Time Income and Adjusted Earnings

    A one-time other income of INR 5 crores has been reported, which, when adjusted, results

HCG Forecasts

Price

Revenue

Earnings

HCG

Income

Balance Sheet

Cash Flow

HCG Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 14.41%, vs industry avg of 10.01%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 2.69% to 3.04%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue588.16709.78861.91986.091,102.611,036.171,560.361,707.631,933.352,166.81
Raw Materialssubtract149.13175.92196.64221.49236.35238.17360.98432.38479.371,758.77
Power & Fuel Costsubtract14.3516.4222.8928.8233.2631.7534.5436.8939.35
Employee Costsubtract100.53121.93157.71184.52208.03195.94233.65275.12308.24
Selling & Administrative Expensessubtract64.5083.00285.43362.38367.58333.50430.81526.94609.42
Operating & Other expensessubtract176.97197.8558.2567.2590.56187.09156.57124.46146.16
Depreciation/Amortizationsubtract44.0856.8371.4685.09148.45159.22158.28163.47174.36199.25
Interest & Other Itemssubtract38.3323.0042.3569.91137.65119.1797.77103.50108.74137.23
Taxes & Other Itemssubtract1.7312.676.65-8.58-12.57-35.2034.0415.5319.5813.25
EPS-0.192.602.38-2.84-12.08-18.084.062.113.464.19
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

HCG Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 26PDF
FY 2023

Annual report

PDF

Investor Presentation

May 25PDF
Feb 9PDF
Nov 10PDF
+3 more
FY 2024

Annual report

PDF

Investor Presentation

Aug 10PDF
FY 2025

Annual Report Pending

Investor Presentation

Feb 16PDF
Nov 9PDF
 

HCG Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareHospitals & Diagnostic Centres

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Healthcare Global Enterprises Ltd145.208.08
Max Healthcare Institute Ltd104.4013.130.13%
Apollo Hospitals Enterprise Ltd103.6012.720.25%
Fortis Healthcare Ltd79.085.540.16%

HCG Stock Price Comparison

Compare HCG with any stock or ETF
Compare HCG with any stock or ETF
HCG
Loading...

HCG Shareholdings

HCG Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

HCG Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 1.52%

Tickertape Separator

HCG Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding71.23%10.04%2.90%2.77%13.06%

Mar 2024

Jun 2024

Sep 2024

Dec 2024

HCG Shareholding History

SepDec '23MarJunSepDec '246.28%6.36%6.74%3.95%4.29%2.77%

Mutual Funds Invested in HCG

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.09%

Top 5 Mutual Funds holding Healthcare Global Enterprises Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
2.5125%1.31%0.19%42/67 (-5)
2.4030%2.03%0.27%18/63 (+4)
2.1535%4.93%1.18%12/31 (-2)

Compare 3-month MF holding change on Screener

HCG Insider Trades & Bulk Stock Deals

Loading...

smallcases containing HCG stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Healthcare Global Enterprises Ltd

Loading...
Safe Haven

Safe Haven

Created by Windmill Capital

HCG's Wtg.
11.56%
CAGR
18.74%

HCG Events

HCG Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

HCG has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

HCG Dividends

Hmm, looks like data is unavailable here. Please come back after some time

HCG Stock News & Opinions

Spotlight
HCG shares up as KKR set to steer the ship

The agreement, which involves a transaction with CVC, a global private markets manager, will see KKR acquire up to 54% of HCG's equity from CVC Asia V at a price of Rs 445 per share. In accordance with the Securities and Exchange Board of India (SEBI) Takeover Regulations, KKR will also conduct an open offer to purchase additional equity shares from public shareholders. Upon completion of the transaction, KKR's total equity stake in HCG is expected to range between 54% and 77%. Dr. BS Ajaikumar, the founder of HCG, will transition to the role of non-executive chairman, where he will focus on driving clinical, academic, and research and development excellence within the organization. The transaction is expected to close by the third quarter of 2025, subject to customary closing conditions and regulatory approvals. Separately, KKR has initiated an open offer to acquire up to 26% of HCG's expanded voting share capital, offering to purchase 3,70,90,327 equity shares at Rs 504.41 per share, for a total consideration of Rs 1870,87,31,842.07. Founded in 1989, HCG is one of India's largest oncology hospital chains. HCG operates 25 medical care centers across 19 cities with best-in-class infrastructure including 2,500 beds, nearly 100 operating theaters and 40 linear accelerator machines (LINACs). Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Healthcare Global Enterprises consolidated net profit rises 22.46% in the December 2024 quarter

Net profit of Healthcare Global Enterprises rose 22.46% to Rs 6.98 crore in the quarter ended December 2024 as against Rs 5.70 crore during the previous quarter ended December 2023. Sales rose 18.89% to Rs 557.55 crore in the quarter ended December 2024 as against Rs 468.95 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales557.55468.95 19 OPM %15.8516.76 - PBDT53.2255.22 -4 PBT-3.3011.06 PL NP6.985.70 22 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Healthcare Global Enterprises revises board meeting date

Healthcare Global Enterprises has revised the meeting of the Board of Directors which was scheduled to be held on 13 February 2025. The meeting will now be held on 14 February 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Healthcare Global Enterprises to hold board meeting

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Healthcare Global Enterprises consolidated net profit rises 32.57% in the September 2024 quarter

Net profit of Healthcare Global Enterprises rose 32.57% to Rs 17.99 crore in the quarter ended September 2024 as against Rs 13.57 crore during the previous quarter ended September 2023. Sales rose 13.69% to Rs 552.47 crore in the quarter ended September 2024 as against Rs 485.96 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales552.47485.96 14 OPM %18.5117.41 - PBDT77.3961.13 27 PBT27.6517.92 54 NP17.9913.57 33 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Healthcare Global Enterprises to acquire oncology biz of HCG NCHRI Oncology LLP

Healthcare Global Enterprises has executed Business Transfer Agreement on 09 November 2024 (BTA), with HCG NCHRI Oncology LLP, a wholly owned subsidiary, for the acquisition of the oncology business of HCG NCHRI Oncology LLP, located at Nagpur, on a slump sale basis. The consideration payable to the Company by the Seller shall not exceed Rs 25 crore, which shall be determined on the effective date of transfer.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Healthcare Global Enterprises to discuss results

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 9 November 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Healthcare Global Enterprises to convene AGM

Healthcare Global Enterprises announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live

6 months agoCapital Market - Live
Earnings
Healthcare Global Enterprises consolidated net profit rises 58.74% in the June 2024 quarter

Net profit of Healthcare Global Enterprises rose 58.74% to Rs 12.08 crore in the quarter ended June 2024 as against Rs 7.61 crore during the previous quarter ended June 2023. Sales rose 14.14% to Rs 524.69 crore in the quarter ended June 2024 as against Rs 459.71 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales524.69459.71 14 OPM %17.3216.16 - PBDT66.0051.53 28 PBT18.9910.52 81 NP12.087.61 59 Powered by Capital Market - Live

7 months agoCapital Market - Live

Broker’s call: HealthCare Global (Add)

8 months agoThe Hindu Businessline

Frequently asked questions

  1. What is the share price of Healthcare Global Enterprises Ltd (HCG) today?

    The share price of HCG as on 21st March 2025 is ₹526.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Healthcare Global Enterprises Ltd (HCG) share?

    The past returns of Healthcare Global Enterprises Ltd (HCG) share are
    • Past 1 week: -0.93%
    • Past 1 month: 3.68%
    • Past 3 months: -5.65%
    • Past 6 months: 20.33%
    • Past 1 year: 46.71%
    • Past 3 years: 96.86%
    • Past 5 years: 487.69%

  3. What are the peers or stocks similar to Healthcare Global Enterprises Ltd (HCG)?
  4. What is the market cap of Healthcare Global Enterprises Ltd (HCG) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Healthcare Global Enterprises Ltd (HCG) is ₹6988.26 Cr as of 21st March 2025.

  5. What is the 52 week high and low of Healthcare Global Enterprises Ltd (HCG) share?

    The 52-week high of Healthcare Global Enterprises Ltd (HCG) is ₹567.70 and the 52-week low is ₹326.

  6. What is the PE and PB ratio of Healthcare Global Enterprises Ltd (HCG) stock?

    The P/E (price-to-earnings) ratio of Healthcare Global Enterprises Ltd (HCG) is 145.20. The P/B (price-to-book) ratio is 8.08.

  7. Which sector does Healthcare Global Enterprises Ltd (HCG) belong to?

    Healthcare Global Enterprises Ltd (HCG) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.

  8. How to buy Healthcare Global Enterprises Ltd (HCG) shares?

    You can directly buy Healthcare Global Enterprises Ltd (HCG) shares on Tickertape. Simply sign up, connect your demat account and place your order.